It took almost 20 years for the NuraVax team to develop and characterize this 3rd generation platform and develop multiple vaccines for elderly people at risk of AD, tauopathies, PD, and α-synucleopathies using mostly NIA and NINDS R21s, R01s, and U01 awards. Of note, because of these data, recently, NIA leadership supported the development of a SARS-CoV-2 MultiTEP-based vaccine for the elderly.